GSA Capital Partners LLP Purchases Shares of 30,464 Structure Therapeutics Inc. (NASDAQ:GPCR)

GSA Capital Partners LLP acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 30,464 shares of the company's stock, valued at approximately $1,337,000. GSA Capital Partners LLP owned about 0.05% of Structure Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of Montreal Can acquired a new position in Structure Therapeutics during the second quarter worth $1,064,000. Bellevue Group AG raised its holdings in Structure Therapeutics by 2,858.7% during the first quarter. Bellevue Group AG now owns 363,926 shares of the company's stock worth $15,598,000 after purchasing an additional 351,626 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new position in Structure Therapeutics during the second quarter worth $1,178,000. abrdn plc raised its holdings in Structure Therapeutics by 132.7% during the third quarter. abrdn plc now owns 217,083 shares of the company's stock worth $9,528,000 after purchasing an additional 123,789 shares during the last quarter. Finally, First Light Asset Management LLC raised its holdings in Structure Therapeutics by 296.1% during the second quarter. First Light Asset Management LLC now owns 590,647 shares of the company's stock worth $23,195,000 after purchasing an additional 441,534 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on GPCR. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating for the company in a research report on Friday, August 9th. Finally, Morgan Stanley began coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $86.80.

Structure Therapeutics Stock Up 1.6 %

Shares of NASDAQ:GPCR traded up $0.59 during midday trading on Thursday, reaching $36.96. The company's stock had a trading volume of 635,450 shares, compared to its average volume of 772,840. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -48.49 and a beta of -3.23. Structure Therapeutics Inc. has a 1 year low of $26.61 and a 1 year high of $66.38. The business has a 50 day moving average price of $39.45 and a 200 day moving average price of $39.84.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.